DrugIn clinical trials

Deramiocel

deramiocel

Allogeneic cardiosphere-derived cell therapy studied for Duchenne muscular dystrophy. Not a gene therapy. On 20 November 2026 the FDA issued a complete response letter: the application does not meet the standard for approval.

News about this drug

Also in the catalogue

Scales

Identifiers

INN
deramiocel

Details

Status
In clinical trials

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.